Versant Ventures V, LLC - Jul 25, 2023 Form 4 Insider Report for Turnstone Biologics Corp. (TSBX)

Role
10%+ Owner
Signature
Versant Ventures V, LLC, By /s/ Max Eisenberg, Chief Operating Officer
Stock symbol
TSBX
Transactions as of
Jul 25, 2023
Transactions value $
$2,700,000
Form type
4
Date filed
7/27/2023, 04:23 PM
Previous filing
Jul 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TSBX Common Stock Conversion of derivative security +2.53M 2.53M Jul 25, 2023 By Versant Venture Capital V, L.P. F1, F2
transaction TSBX Common Stock Conversion of derivative security +192K 192K Jul 25, 2023 By Versant Venture Capital V (Canada) LP F1, F3
transaction TSBX Common Stock Conversion of derivative security +84.3K 84.3K Jul 25, 2023 By Versant Ophthalmic Affiliates Fund I, L.P. F1, F4
transaction TSBX Common Stock Conversion of derivative security +76.1K 76.1K Jul 25, 2023 By Versant Affiliates Fund V, L.P. F1, F5
transaction TSBX Common Stock Conversion of derivative security +275K 275K Jul 25, 2023 By Versant Vantage II, L.P. F1, F6
transaction TSBX Common Stock Purchase $2.37M +197K +7.81% $12.00 2.73M Jul 25, 2023 By Versant Venture Capital V, L.P. F2
transaction TSBX Common Stock Purchase $180K +15K +7.81% $12.00 207K Jul 25, 2023 By Versant Venture Capital V (Canada) LP F3
transaction TSBX Common Stock Purchase $78.9K +6.58K +7.8% $12.00 90.9K Jul 25, 2023 By Versant Ophthalmic Affiliates Fund I, L.P. F4
transaction TSBX Common Stock Purchase $71.3K +5.94K +7.81% $12.00 82K Jul 25, 2023 By Versant Affiliates Fund V, L.P. F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TSBX Series A Preferred Stock Conversion of derivative security $0 -7.9M -100% $0.00* 0 Jul 25, 2023 Common Stock 989K By Versant Venture Capital V, L.P. F1, F2
transaction TSBX Series A Preferred Stock Conversion of derivative security $0 -601K -100% $0.00* 0 Jul 25, 2023 Common Stock 75.3K By Versant Venture Capital V (Canada) LP F1, F3
transaction TSBX Series A Preferred Stock Conversion of derivative security $0 -263K -100% $0.00* 0 Jul 25, 2023 Common Stock 33K By Versant Ophthalmic Affiliates Fund I, L.P. F1, F4
transaction TSBX Series A Preferred Stock Conversion of derivative security $0 -238K -100% $0.00* 0 Jul 25, 2023 Common Stock 29.7K By Versant Affiliates Fund V, L.P. F1, F5
transaction TSBX Series B-1 Preferred Stock Conversion of derivative security $0 -3.53M -100% $0.00* 0 Jul 25, 2023 Common Stock 442K By Versant Venture Capital V, L.P. F1, F2
transaction TSBX Series B-1 Preferred Stock Conversion of derivative security $0 -269K -100% $0.00* 0 Jul 25, 2023 Common Stock 33.6K By Versant Venture Capital V (Canada) LP F1, F3
transaction TSBX Series B-1 Preferred Stock Conversion of derivative security $0 -118K -100% $0.00* 0 Jul 25, 2023 Common Stock 14.7K By Versant Ophthalmic Affiliates Fund I, L.P. F1, F4
transaction TSBX Series B-1 Preferred Stock Conversion of derivative security $0 -106K -100% $0.00* 0 Jul 25, 2023 Common Stock 13.3K By Versant Affiliates Fund V, L.P. F1, F5
transaction TSBX Series B-2 Preferred Stock Conversion of derivative security $0 -7.65M -100% $0.00* 0 Jul 25, 2023 Common Stock 958K By Versant Venture Capital V, L.P. F1, F2
transaction TSBX Series B-2 Preferred Stock Conversion of derivative security $0 -582K -100% $0.00* 0 Jul 25, 2023 Common Stock 72.9K By Versant Venture Capital V (Canada) LP F1, F3
transaction TSBX Series B-2 Preferred Stock Conversion of derivative security $0 -255K -100% $0.00* 0 Jul 25, 2023 Common Stock 31.9K By Versant Ophthalmic Affiliates Fund I, L.P. F1, F4
transaction TSBX Series B-2 Preferred Stock Conversion of derivative security $0 -230K -100% $0.00* 0 Jul 25, 2023 Common Stock 28.8K By Versant Affiliates Fund V, L.P. F1, F5
transaction TSBX Series C Preferred Stock Conversion of derivative security $0 -1.12M -100% $0.00* 0 Jul 25, 2023 Common Stock 140K By Versant Venture Capital V, L.P. F1, F2
transaction TSBX Series C Preferred Stock Conversion of derivative security $0 -85.2K -100% $0.00* 0 Jul 25, 2023 Common Stock 10.7K By Versant Venture Capital V (Canada) LP F1, F3
transaction TSBX Series C Preferred Stock Conversion of derivative security $0 -37.3K -100% $0.00* 0 Jul 25, 2023 Common Stock 4.67K By Versant Ophthalmic Affiliates Fund I, L.P. F1, F4
transaction TSBX Series C Preferred Stock Conversion of derivative security $0 -33.7K -100% $0.00* 0 Jul 25, 2023 Common Stock 4.22K By Versant Affiliates Fund V, L.P. F1, F5
transaction TSBX Series D Preferred Stock Conversion of derivative security $0 -2.2M -100% $0.00* 0 Jul 25, 2023 Common Stock 275K By Versant Vantage II, L.P. F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.
F2 Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F3 Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Jerel C. Davis is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Canada V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F4 Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F5 Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Affiliates, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F6 Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. Jerel C. Davis is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Canada V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.